Summary
CVS Health Corporation (CVS) reported a solid financial performance for the second quarter and the first half of 2013. The company demonstrated revenue growth, driven by both its Pharmacy Services and Retail Pharmacy segments. Key to this growth was an increase in prescription volume and favorable drug cost inflation in specialty pharmacy, alongside gains from new store openings in the retail segment. Despite challenges from increasing generic drug sales, which typically lower revenue per prescription, CVS Health managed to improve its gross profit margins due to higher generic dispensing rates and cost-saving initiatives. Profitability also saw a significant boost, with net income and earnings per share increasing compared to the prior year. The company continued its share repurchase program, returning capital to shareholders while maintaining a strong liquidity position. Management appears confident in the company's ability to navigate industry challenges, including regulatory scrutiny and competitive pressures, and remains focused on strategic growth and cost management.
Financial Highlights
55 data points| Revenue | $31.25B |
| Cost of Revenue | $25.41B |
| Gross Profit | $5.84B |
| Operating Expenses | $3.87B |
| Operating Income | $1.97B |
| Interest Expense | $127.00M |
| Net Income | $1.12B |
| EPS (Basic) | $0.92 |
| EPS (Diluted) | $0.91 |
| Shares Outstanding (Basic) | 1.23B |
| Shares Outstanding (Diluted) | 1.24B |
Key Highlights
- 1Net revenues increased by 1.7% to $31.2 billion for the three months ended June 30, 2013, and by 0.8% to $62.0 billion for the six months ended June 30, 2013, compared to the prior year periods.
- 2Gross profit increased by $387 million to $5.8 billion for the three months and by $856 million to $11.4 billion for the six months ended June 30, 2013.
- 3Operating profit increased by $260 million to $2.0 billion for the three months and by $556 million to $3.7 billion for the six months ended June 30, 2013.
- 4Net income attributable to CVS Caremark was $1.12 billion ($0.91 per diluted share) for the three months ended June 30, 2013, up from $0.97 billion ($0.75 per diluted share) in the prior year.
- 5The company repurchased approximately $748 million of its common stock during the six months ended June 30, 2013, under its $6.0 billion share repurchase program.
- 6The Pharmacy Services segment saw a notable improvement in gross profit margin, driven by increased generic dispensing rates and cost-saving initiatives.
- 7The Retail Pharmacy segment experienced growth in net revenues, primarily from new store openings and increased pharmacy same-store sales, despite pressure from generic drug conversions.